Key facts
- Vyriad’s last known valuation is $218.6M (Dec 2025).
- It has raised $113.3M across 1 recorded rounds; the latest was Early Stage VC ($24.4M) in Oct 2019.
- Notable investors include Mirae Asset Capital, Mayo Clinic Ventures, City of Rochester, Minnesota Department of Employment and Economic Development, Regeneron Pharmaceuticals — 8 tracked in total.
- Vyriad has filed 1 Form D with the SEC, most recently Nov 2019 ($24.4M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Vyriad
Funding rounds
1 roundsAbout Vyriad
Developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells. This technology facilitates oncolytic virotherapy, in vivo gene therapies, and editing applications, enabling clinicians with oncolytic viruses as monotherapies and in combination with immune-oncology drugs in multiple cancer indications.
- Sector
- Healthcare
- HQ
- Rochester, MN, United States
- Founded
- 2015
- Employees
- 90
- Website
- vyriad.com/
- Ownership
- Privately Held (backing)
Vyriad doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vyriad shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vyriad in its N-PORT filings yet. We sweep new filings monthly.